Featured Stocks
Helix TCS Inc (OTCMKTS: HLIX) Becoming a Cannabis Powerhouse Slowly But Steadily
The marijuana industry is, without a doubt, a rapidly growing market. However, several regulations keep on changing, and operators highly rely on the most trusted technology solutions to focus their business as well as navigate complexities.
Therefore, only the best stock is what they look after. Likely enough, Helix TCS Inc (OTCMKTS: HLIX) provides the marijuana industry’s most powerful as well as effective critical infrastructure services. Notably, the firm has the market’s leading brands such as BioTrackTHC, Amercanex, Helix Security, and CannaBase with it, which help the company to meet and exceed their requirements.
HLIX 101
Helix TCS Inc. is the leading provider of ancillary services for the marijuana industry in the US. The stock helps owners as well as operators of the licensed marijuana business to stay competitive and compliant as they mitigate risks.
The stock’s products are available to over 2,000 customer locations in almost 33 states and 5 countries. Besides, they have (thus far) processed more than $18 billion in marijuana sales. The numbers may seem impressive, but what lies ahead is somewhat more promising.
HLIX Price Analysis
One area that HLIX stock has not impressed lately is its price, which has been on the downtrend over the past year now. However, it has to be believed that similar market segments have not been very popular in that period, and hence, the declining price tendency may be having last breaths.
Currently, the price of Helix stock stands at $1.68, and it may not be long before we start seeing another upward trajectory. Nevertheless, the stock is off its 52-week high of about $4.01 that it experienced a year ago.
The latest developments, as well as acquisitions the stock has made, may soon prove to be the catalysts for Helix to hit new highs.
Helix TCS, Inc. Doing Everything Right for a Breakthrough
In ensuring that the stock remains on track for a breakout, it has thus far made several acquisitions as well as developments. The results of the events may have been highlighted from the report on Helix’s Q1 of 2019.
Preparations for Cannabis as a Commodity
The company has already prepared for cannabis as a commodity by acquiring Amercanex International Exchange. The acquisition is a step further for the stock positioning itself as the leader in the development of modern marijuana market.
Acquired merely two months ago, Amercanex International Exchange is the most influential marijuana electronic trading platforms. Its acquisition provides Helix TCS with a Sophisticated Electronic Communications Network (ECN) which can integrate blockchain technology in facilitating real-time transactions in the market.
It also enables transaction capabilities in several cannabis markets in the US and internationally.
The Contract Extension with Hawaii
Not too long ago, the stock extended its cannabis tracking contract with Hawaii. In the one-year contract, its subsidiary Bio Track THC will be providing the state with medical cannabis traceability system.
Further international Footprint for Helix TCS into Europe: The stock also expanded its reach with licensed cannabis cultivators as well as manufactures in the UK using BioTrackTHC. By doing so they’ll be able to meet the ever-expanding demand in the industry.
The Leading Point of Sale
The company was ranked top revenue-generating ancillary business two months ago by the Cannabis Business Executive. It’s a significant achievement which not only shows that the stock is doing great but also indicates that Helix is on the right track now.
Subsequently, all the developments had shown positive results in the recent Q1 2019 report. If we talk about the numbers, the revenues increased 199% to $3.37 million with a gross profit of $1.45 million, a gross margin of 43%.
What Now for Helix TCS?
As cannabis moves closer to federal legalization in the United States, Helix TCS is one of the best stocks well positioned to proliferate in line with the entire market. With a steady and smart leadership, Helix is poised for way more growth than many think it can.
For the latest updates on HLIX and the hottest MJ stocks, sign up below!
Disclosure: We have no position in HLIX and have not been compensated for this article.
Image courtesy of Pexels
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
About OTCMKTS:DECN
Decision Diagnostics bills itself…
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
About CytoDyn
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…
On the OTC Markets, there are a lot of pump and dumps. Investors need to protect themselves from these types of scams and one, in particular, is Rainmaker Worldwide Inc (OTCMKTS:RAKR).
OTCMKTS:RAKR Price Action
While the price action recently has been positive, it’s just a matter of time before RAKR is trading in the double zeros again. It’s not a question of if it will happen, but when it will happen.
About Rainmaker Worldwide
According to its profile, Rainmaker Worldwide Inc. is headquartered in Peterborough, Canada, with an innovation and manufacturing center in Rotterdam, Netherlands. Its patented water technology provides economical drinking water wherever it’s needed and at scale. Rainmaker builds two types of energy-efficient, fresh water-producing technologies to participate in this opportunity. 1. Air-to-Water, which harvests fresh water from humidity in the atmosphere. 2. Water-to-Water, which transforms seawater or polluted water into drinking water.
Lack of Fundamentals
The biggest concern facing investors is the lack of fundamentals. OTCMKTS:RAKR has a current market cap of $41 milli0n, but reported just $1000 in sales in the quarter ending September 30, 2019. Making matters worse is that Rainmaker burned through $524,000 in the quarter. Throughout its history, Rainmaker has lost $14.7 million.
EU Horizon 2020 Project and $2.5 million grant
Last September, Rainmaker touted the award of the European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. According to the press…
Online Dispensary Sales Boom – What Consumers Need to Know to Stay Safe…
Why the ACMPR Is So Popular with Medical Marijuana Patients in Canada
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
Why Buy From Marijuana Seed Banks?
What Do Investors See In Medical Marijuana Stock (OTCMKTS:MJNA)?
Rainmaker Worldwide Inc (OTCMKTS:RAKR) Looking For Bagholders
Is Tilray Inc (NASDAQ:TLRY) A Buy Or Sell?
Is Cronos Stock (TSE:CRON)(NASDAQ:CRON) A Buy?
Is Neptune Wellness Solutions Inc (TSE:NEPT)(NASDAQ:NEPT) A Good Bet Right Now?
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
Helix TCS Inc (OTCMKTS: HLIX) Becoming a Cannabis Powerhouse Slowly But Steadily
5 Marijuana Stocks To Own In 2020 and Why
Why OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Is A Promising Stock In 2020
Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB): The Pain May Be Over
Planet 13 Stock (CNSX:PLTH) (OTCMKTS:PLNHF): Is It A Buy Or Sell?
CannTrust Holdings Inc (NYSE:CTST): A Blessing In Disguise?
GrowLife Stock (OTCMKTS:PHOT) Primed For Breakout And Here’s Why
Hemp Stock (OTCMKTS:HEMP) Climbing The Ladder
